MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596923 | Name: Jmv 179

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Jmv 179 is a cholecystokinin receptor antagonist.

Chemical Structure

Jmv 179
Jmv 179
CAS#119386-87-7

Theoretical Analysis

MedKoo Cat#: 596923

Name: Jmv 179

CAS#: 119386-87-7

Chemical Formula: C51H67N7O15S

Exact Mass: 1049.4416

Molecular Weight: 1050.19

Elemental Analysis: C, 58.33; H, 6.43; N, 9.34; O, 22.85; S, 3.05

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Jmv 179; Jmv-179; Jmv179;
IUPAC/Chemical Name
(6S,9S,15R,18S,21S)-15-((1H-indol-3-yl)methyl)-9,18-dibutyl-2,2-dimethyl-4,7,10,13,16,19-hexaoxo-21-(phenethoxycarbonyl)-6-(4-(sulfooxy)benzyl)-3-oxa-5,8,11,14,17,20-hexaazatricosan-23-oic acid
InChi Key
IOXMTWKALARBDR-DNOUOQLUSA-N
InChi Code
InChI=1S/C51H67N7O15S/c1-6-8-18-38(55-47(64)40(58-50(67)72-51(3,4)5)27-33-21-23-35(24-22-33)73-74(68,69)70)45(62)53-31-43(59)54-41(28-34-30-52-37-20-14-13-17-36(34)37)48(65)56-39(19-9-7-2)46(63)57-42(29-44(60)61)49(66)71-26-25-32-15-11-10-12-16-32/h10-17,20-24,30,38-42,52H,6-9,18-19,25-29,31H2,1-5H3,(H,53,62)(H,54,59)(H,55,64)(H,56,65)(H,57,63)(H,58,67)(H,60,61)(H,68,69,70)/t38-,39-,40-,41+,42-/m0/s1
SMILES Code
O=C(O)C[C@@H](C(OCCC1=CC=CC=C1)=O)NC([C@H](CCCC)NC([C@@H](CC2=CNC3=C2C=CC=C3)NC(CNC([C@H](CCCC)NC([C@H](CC4=CC=C(OS(=O)(O)=O)C=C4)NC(OC(C)(C)C)=O)=O)=O)=O)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,050.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Quesada A, Micevych P. Estrogen and CCK1 receptor modification of mu-opioid receptor binding in the cortex of female rats. Brain Res. 2006 Feb 16;1073-1074:316-20. Epub 2006 Feb 10. PubMed PMID: 16472782. 2: Gigoux V, Escrieut C, Fehrentz JA, Poirot S, Maigret B, Moroder L, Gully D, Martinez J, Vaysse N, Fourmy D. Arginine 336 and asparagine 333 of the human cholecystokinin-A receptor binding site interact with the penultimate aspartic acid and the C-terminal amide of cholecystokinin. J Biol Chem. 1999 Jul 16;274(29):20457-64. PubMed PMID: 10400673. 3: Kennedy K, Gigoux V, Escrieut C, Maigret B, Martinez J, Moroder L, Fréhel D, Gully D, Vaysse N, Fourmy D. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. J Biol Chem. 1997 Jan 31;272(5):2920-6. PubMed PMID: 9006937. 4: Camby I, Salmon I, Oiry C, Galleyrand JC, Nagy N, Danguy A, Brotchi J, Pasteels JL, Martinez J, Kiss R. The influence of gastrin and/or cholecystokinin antagonists on the proliferation of three human astrocytic tumor cell lines. Neuropeptides. 1996 Oct;30(5):433-7. PubMed PMID: 8923504. 5: Talkad VD, Patto RJ, Metz DC, Turner RJ, Fortune KP, Bhat ST, Gardner JD. Characterization of the three different states of the cholecystokinin (CCK) receptor in pancreatic acini. Biochim Biophys Acta. 1994 Oct 20;1224(1):103-16. PubMed PMID: 7524683. 6: Hadjiivanova C, Petkov VV, Kehayov R, Martinez J. Behavioural effects of two cholecystokinin analogues: JMV 236 and JMV 179. Neuropeptides. 1994 Sep;27(3):163-7. PubMed PMID: 7816187. 7: Poirot SS, Escrieut C, Dufresne M, Martinez J, Bouisson M, Vaysse N, Fourmy D. Photoaffinity labeling of rat pancreatic cholecystokinin type A receptor antagonist binding sites demonstrates the presence of a truncated cholecystokinin type A receptor. Mol Pharmacol. 1994 Apr;45(4):599-607. PubMed PMID: 8183238. 8: Yule DI, Williams JA. CCK antagonists reveal that CCK-8 and JMV-180 interact with different sites on the rat pancreatic acinar cell CCKA receptor. Peptides. 1994;15(6):1045-51. PubMed PMID: 7527529. 9: Silvente Poirot S, Hadjiivanova C, Escrieut C, Dufresne M, Martinez J, Vaysse N, Fourmy D. Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179. Eur J Biochem. 1993 Mar 1;212(2):529-38. PubMed PMID: 8444190. 10: Nagain C, Galas MC, Lignon MF, Rodriguez M, Martinez J, Rozé C. Synthetic CCK8 analogs with antagonist activity on pancreatic receptors: in vivo study in the rat, compared to non-peptidic antagonists. Pancreas. 1991 May;6(3):275-81. PubMed PMID: 1713671.